newsfilter
← Latest News
GlobeNewswire·

Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights

EQ

Phase 1 proof-of-mechanism study of EQ504 on track to initiate in mid-2026, with data expected approximately six months thereafter Equillium appoints Snehal Naik, Ph.D., as Chief Development Officer to lead clinical